Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic, premalignant clonal plasma cell proliferative disorder [1–4]. It was initially referred to as essential hyperglobulinemia by Jan Waldenström, as well as several other terms such as benign, idiopathic, asymptomatic, nonmyelomatous, discrete, cryptogenic, and rudimentary monoclonal gammopathy; dysimmunoglobulinemia; lanthanic monoclonal gammopathy; idiopathic paraproteinemia; and asymptomatic paraimmunoglobulinemia [5, 6]. However, since there is an indefinite risk of progression to multiple myeloma (MM) or related disorder such as macroglobulinemia (WM) or amyloidosis (AL), the term MGUS is now the accepted nomenclature [1, 2, 7, 8]. Smoldering multiple myeloma (SMM) is a clinically defined premalignant stage between MGUS and MM [9, 10]. MGUS and SMM must be differentiated from MM, and from a number of related plasma cell disorders using the criteria listed in see Table 1.2 in Chap. 1 [8, 11].
Original language | English (US) |
---|---|
Title of host publication | Multiple Myeloma |
Subtitle of host publication | Diagnosis and Treatment |
Publisher | Springer New York |
Pages | 65-80 |
Number of pages | 16 |
ISBN (Electronic) | 9781461485209 |
ISBN (Print) | 9781461485193 |
DOIs | |
State | Published - Jan 1 2014 |
ASJC Scopus subject areas
- Medicine(all)